Reviva updates RECOVER OLE enrollment: 358 enrolled, 23 completed 12 months, NDA on track for Q4 2025

REVIVA PHARMACEUTICALS HOLDINGS, INC.

358 patients enrolled; 223 currently on treatment across USA, Europe, and Asia.
23 patients have completed 12 months of treatment; targeting 100 for NDA submission.
Brilaroxazine generally well tolerated in acute and stable schizophrenia patients.
Topline 12-month safety data expected in Q4 2024; NDA submission planned for Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.